When a US federal judge rejected patents by Myriad Genetics on the BRCA1 and BRCA2 genes in late March, it put many in the biotech industry on edge after years of making similar claims of their own. Kyle Jensen, a director with the nonprofit PIPRA, has been tracking the patent push, and in 2005 he coauthored a study on human genome patenting (Science 310, 239–240, 2005). Below, Jensen provided Nature Medicine with updated data from 2009; of special note are more than 5,600 patents that claim rights to human DNA sequences. If these patents make specific claims similar to those rejected in the Myriad case, they, too, could be ruled invalid.